Bivalent and monovalent Hepatitis A vaccines conferred durable immunity after a median of 23 years, with seroprotection rates of 97.0% and 94.6%, respectively (p=0.28).
Cohort (n=334)
Does bivalent hepatitis A vaccine improve long-term seroprotection compared to monovalent vaccine in healthcare workers?
Both monovalent and bivalent hepatitis A vaccines confer durable immunity for over two decades in healthcare workers.
Absolute Event Rate: 97% vs 94.6%
p-value: p=0.28
test and logistic regression (STATA MP 11). A total of 334 participants were included (167 per group; mean age 31 vs. 36 years). After a median of 23 years since vaccination, seroprotection rates were 94.6% for the monovalent and 97.0% for the bivalent vaccine groups (p = 0.28). Mean anti-HAV IgG concentrations were significantly higher in the bivalent vaccine group (10.9 ± 4.6 IU/mL) than in the monovalent group (8.3 ± 4.6 IU/mL; p < 0.001). No associations were observed with sex or behavioural factors, and younger age was the only independent predictor of higher antibody levels (β = 0.32; 95% CI, 0.10-0.43; p < 0.001). These findings demonstrate that protective HAV antibody levels persist for more than two decades after vaccination. Both monovalent and bivalent vaccines confer durable immunity, supporting the continued inclusion of HAV vaccination in national immunisation programs and occupational health strategies.
Noviello et al. (2026) conducted a cohort in Hepatitis A Virus Immunity (n=334). Bivalent Hepatitis A vaccine vs. Monovalent Hepatitis A vaccine was evaluated on Seroprotection rates (p=0.28). Bivalent and monovalent Hepatitis A vaccines conferred durable immunity after a median of 23 years, with seroprotection rates of 97.0% and 94.6%, respectively (p=0.28).